Myomo (MYO)
(Delayed Data from AMEX)
$3.82 USD
+0.11 (2.96%)
Updated Sep 25, 2024 03:34 PM ET
After-Market: $3.82 +0.05 (1.19%) 5:32 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Myomo, Inc. [MYO]
Reports for Purchase
Showing records 1 - 20 ( 120 total )
Company: Myomo, Inc.
Industry: Medical - Products
Medicare Revenue Ramping Up; Higher $7.50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Myomo, Inc.
Industry: Medical - Products
Building Up to a Strong 2024 as Medicare Reimbursement Gets Underway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Myomo, Inc.
Industry: Medical - Products
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Entering High Growth Period Following CMS Reimbursement Approval; Initiating With Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
1Q:23 Revenue In Line With Expectations; We Narrow Our Loss Estimates For 2023 And 2024
Provider: Sidoti CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Forecast Narrower Losses In 2023-2024 Due To Cost Cuts And Improving Reimbursement
Provider: Sidoti CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
4Q:22 Revenue In Line With Expectation,Maintain $6 Price Target
Provider: Sidoti CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Raises $6 Million Through An Equity Offering; Adjust Loss-Per-Share Estimates For 2023-2024
Provider: Sidoti CSR
Analyst: Research Department